Aligos Therapeutics Inc ALGS:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
25.83quote price arrow down-1.50 (-5.49%)
Volume
55,052
52 week range
12.82 - 37.51

...

Loading . . .

KEY STATS

  • Open27.19
  • Day High27.92
  • Day Low25.56
  • Prev Close27.33
  • 52 Week High37.51
  • 52 Week High Date01/20/21
  • 52 Week Low12.82
  • 52 Week Low Date10/20/20
  • Market Cap984.64M
  • Shares Out38.12M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.42
  • P/E (TTM)-18.23
  • Fwd P/E (NTM)-7.77
  • EBITDA (MRQ)-72.105M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)32.17%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Aligos Therapeutics Inc News

There is no recent news for this security.

Latest ALGS News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular...
Lawrence Blatt Ph.D.
Chief Executive Officer
Leonid Beigelman Ph.D.
President
Julian Symons Ph.D.
Executive Vice President
Brian Dowd CPA
Executive Vice President
Lucinda Quan J.D.
Executive Vice President
Address
One Corporate Dr., 2nd Floor, 2nd Floor
South San Francisco, CA
94080
United States